NASDAQ:VBIV
VBI Vaccines Inc. Stock News
$0.583
+0.0131 (+2.30%)
At Close: May 02, 2024
VBI Vaccines, Inc. (VBIV) Reports Q4 Loss, Lags Revenue Estimates
10:37am, Tuesday, 02'nd Mar 2021
VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 0.00% and -62.73%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
VBI Vaccines Announces U.S. FDA Acceptance of BLA Filing for VBI's 3-Antigen Prophylactic Hepatitis B Vaccine
08:00am, Tuesday, 02'nd Feb 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vacc
10 Short Squeeze Candidates Under $10
08:36am, Saturday, 30'th Jan 2021
The movement of retail traders against hedge funds has caused several stocks to spike. Many of the top movers have been stocks that have a high percentage of their floated shares short, causing what's
VBI Vaccines (VBIV) Provides Updates on COVID-19 Vaccine
03:03pm, Friday, 22'nd Jan 2021
VBI Vaccines (VBIV) plans to begin a phase I/II study of monovalent vaccine candidate, VBI-2902, in the first quarter of 2021.
Week 3 MDA Breakout Stocks - January 2021: Short-Term Picks To Give You An Edge
05:43am, Sunday, 17'th Jan 2021
Week 3 MDA Breakout Stocks - January 2021: Short-Term Picks To Give You An Edge
Why Novartis, BioVie, Esperion And VBI Are Moving Today
11:47am, Friday, 15'th Jan 2021
Esperion Therapeutics (NASDAQ: ESPR) shares are trading lower after Bank of America Securities downgraded the stock from Buy to Neutral and announced a price target of $35 per share. Esprit Holdings i
Why VBI Vaccines Stock Is Vaulting Higher Today
11:28am, Friday, 15'th Jan 2021
The company reported good news from a study of its hepatitis B vaccine.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vacc
8 Penny Stocks to Avoid in 2021
03:24pm, Monday, 11'th Jan 2021
With risk-return not in your favor, steer clear of these 8 penny stocks, all of which could see big declines as the new year unfolds. Chesapeake Energy (OTCMKTS:CHKAQ) Genius Brands (NASDAQ:GNUS) Hert
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vacc
VBI Vaccines to Discuss Hepatitis B Portfolio in Virtual Fireside Chat Hosted by Raymond James
08:00am, Wednesday, 02'nd Dec 2020
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vacc
VBI Vaccines Announces Submission of Biologics License Application to FDA for 3-Antigen Prophylactic Hepatitis B Vaccine
08:00am, Tuesday, 01'st Dec 2020
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vacc
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vacc
VBI Vaccines' (VBIV) Early Data on HBV Candidate Positive
10:45am, Thursday, 19'th Nov 2020
VBI Vaccines' (VBIV) early-stage hepatitis B virus immunotherapeutic candidate, VBI-2601, achieves promising immune response in patients on interim analysis.
VBI Vaccines Announces Positive Interim Phase 1b/2a Data for Hepatitis B Immunotherapeutic in Patients with Chronic Infection
08:00am, Wednesday, 18'th Nov 2020
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vacc
